Many people in the industry often confuse the various phases of clinical trials, especially when it comes to FDA terminology. For instance, Phase I focuses primarily on safety while also examining dosing, which is crucial for patient compliance later on. It’s interesting how these definitions can impact marketing strategies and patient recruitment — what are everyone’s thoughts on this?